Monday, August 31, 2020
Saturday, August 29, 2020
Friday, August 28, 2020
Thursday, August 27, 2020
Monday, August 24, 2020
Pfizer enters phase three Covid-19 vaccine trial
Pfizer and BioNTech Provide Encouraging Data:
On 20 August 2020,New York-based Pfizer and its Mainz, Germany partner BioNTech released additional Phase-1 trial safety and immunogenicity data for their COVID-19 vaccine candidate.The early trial showed that,at 30 micrograms,7 days after the second dose of BNT162b2, the dose elicited SARS-CoV2 antibodies that in younger patients (18-55 years) were 3.8 times more than COVID-19 convalescent patient antibodies; and in older patients (65-85 years) elicited 1.6 times more antibodies than in convalescent patients.
What is more, across all populations,BNT162b2 was well- tolerated with mild to moderate fever in less than 20% of the participants.The companies continue to analyse the Phase 1 data in the US and Germany, they said, while they have progressed into the advanced Phase 2/3 trials, with more than 11,000 participants having already been dosed.Assuming clinical success of the advanced trials,they intend to apply for regulatory review as early as October 2020 and,if obtained, to supply up to 100 million doses worldwide by the end of 2020,and about 1.3 billion doses worldwide by the end of 2021.
As reported earlier, the Phase 1 trials indicated production of both antibodies and disease-fighting T-cells in the participants.Two doses of this vaccine candidate are administered to each participant three weeks apart.
Pfizer Inc (PFE), BioNTech SE (BNTX)
On 20 August 2020,New York-based Pfizer and its Mainz, Germany partner BioNTech released additional Phase-1 trial safety and immunogenicity data for their COVID-19 vaccine candidate.The early trial showed that,at 30 micrograms,7 days after the second dose of BNT162b2, the dose elicited SARS-CoV2 antibodies that in younger patients (18-55 years) were 3.8 times more than COVID-19 convalescent patient antibodies; and in older patients (65-85 years) elicited 1.6 times more antibodies than in convalescent patients.
What is more, across all populations,BNT162b2 was well- tolerated with mild to moderate fever in less than 20% of the participants.The companies continue to analyse the Phase 1 data in the US and Germany, they said, while they have progressed into the advanced Phase 2/3 trials, with more than 11,000 participants having already been dosed.Assuming clinical success of the advanced trials,they intend to apply for regulatory review as early as October 2020 and,if obtained, to supply up to 100 million doses worldwide by the end of 2020,and about 1.3 billion doses worldwide by the end of 2021.
As reported earlier, the Phase 1 trials indicated production of both antibodies and disease-fighting T-cells in the participants.Two doses of this vaccine candidate are administered to each participant three weeks apart.
Pfizer Inc (PFE), BioNTech SE (BNTX)
Friday, August 21, 2020
Hubble Snaps Close-Up of Celebrity Comet NEOWISE,may help reveal conditions in the early solar system
Hubble Snaps Close-Up of Celebrity Comet NEOWISE: The Hubble Space Telescope has snapped the closest images yet of the sky's latest visitor to make headlines, comet NEOWISE, after it passed by the Sun. This is the first time Hubble has photographed a comet of this brightness at such resolution after this close of a pass by the Sun.
Thursday, August 20, 2020
Monday, August 17, 2020
Friday, August 14, 2020
Thursday, August 13, 2020
Monday, August 10, 2020
Saturday, August 8, 2020
Thursday, August 6, 2020
Monday, August 3, 2020
Subscribe to:
Posts (Atom)